文献速递乳腺癌放疗姑息放疗与转移瘤

CDK4/6抑制剂联合放疗:文献综述

CDK 4/6 inhibitors combined with radiotherapy: A review of literature.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-12-01

本文综述了CDK4/6抑制剂(palbociclib、ribociclib、abemaciclib)联合放疗在转移性乳腺癌中的已发表数据,旨在了解该联合方案可能的毒性。临床前数据提示两者可能具有协同效应,但联合毒性数据稀缺。

要点

  • CDK4/6抑制剂与激素治疗联用获批治疗HR阳性/HER2阴性晚期乳腺癌。
  • 临床前数据提示CDK4/6抑制剂与放疗可能具有协同效应。
  • CDK4/6抑制剂联合放疗的毒性数据稀缺,需关注安全性。

核心结论

  • 本综述旨在汇总CDK4/6抑制剂联合放疗的已发表数据,以理解其在转移性乳腺癌中可能的毒性。

研究设计与样本

  • 文献综述,聚焦CDK4/6抑制剂联合放疗的使用。

主要发现

  • 临床前数据提示CDK4/6抑制剂与放疗可能具有协同效应。
  • CDK4/6抑制剂联合放疗的毒性数据稀缺。

局限性

  • 关于CDK4/6抑制剂联合放疗的毒性数据稀缺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) namely palbociclib, ribociclib and abemaciclib were granted approval by the European Medicines Agency (EMA) between 2017 and 2018. They are currently prescribed in combination with hormone therapy to treat hormone receptor positive, HER2 negative metastatic or locally advanced breast cancer. Their combination with radiotherapy raises safety concerns as preclinical data enlightened their possible synergistic effect. Moreover, data about toxicity when combining CDK4/6i with radiotherapy are scarce. This review of literature focused on the use of CDK4/6i combined with radiotherapy. It aimed at listing every published data about such combination so as to understand its possible resulting toxicity in metastatic breast cancer.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bosacki C, Bouleftour W, Sotton S, et al. CDK 4/6 inhibitors combined with radiotherapy: A review of literature. Clin Transl Radiat Oncol. 2020. PMID: 33319074. doi:10.1016/j.ctro.2020.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。